Ethics, justification and the prevention of spina bifida

Journal of Medical Ethics

Volumn 33, Issue 9, 2007, Pages 501-507

  Gagen, Wendy Jane ^a,b   Bishop, Jeffrey P ^a,b  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOETHICS; ECHOGRAPHY; ETHICS; FEMALE; HUMAN; METHODOLOGY; PREGNANCY; PRENATAL DIAGNOSIS; SPINAL DYSRAPHISM;

BIOETHICAL ISSUES; FEMALE; HUMANS; PREGNANCY; PRENATAL DIAGNOSIS; SPINAL DYSRAPHISM;

EID: 34548807524     PISSN: 03066800     EISSN: None     Source Type: Journal    
DOI: 10.1136/jme.2006.018697     Document Type: Article

References (42)

1. Leighton AH, Gordon YB, Kitau MJ, et al. Levels of alpha-fetoprotein in maternal blood as a screening test for fetal neural-tube defect. Lancet 1975;7943:1012-15.
2. Jonsen A R. The birth of bioethics. Oxford: Oxford University Press, 1998.
3. Peterson A, Lupton D. The new public health: health and self in the age of risk. London: Sage, 1996.
4. Berridge V. Health and society in Britain since 1939. Cambridge: Cambridge University Press, 1999.
5. Baggot R. Public health policy and politics. Basingstoke: Macmillan, 2000.
6. Department of Health and Social Security, Department of Education and Science Scottish Office and Welsh Office. Prevention and health. London: HMSO, 1977 (Cmnd, 7047).
7. Shorter E. The history of the doctor-patient relationship. In: Bynum WF, Porter R, eds. Companion encyclopaedia of the history of medicine. London: Routledge, 1993.
8. Skrabanek P. The death of humane medicine and the rise of coercive healthism. Bury St Edmunds: The Social Affairs Unit, 1994.
9. Health Departments of Great Britain and Northern Ireland. Prevention and health everybody's business. A reassessment of public and personal health. London: HMSO, 1976.
10. Brock DJH, Sutcliffe RG. Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida. Lancet 1972; 7770:198-9.
11. Campbell S, Pryse-Davis J, Colart TM, et al. Ultrasound in the diagnosis of spina bifida. Lancet 1975;7915:1065-8.
12. Leek AE, Leighton AH, Kitau MJ, et al. Prospective diagnosis of spina bifida. Lancet 1974;7895:1551.
13. UK Collaborative Study on Alpha-fetoprotein in Relation to Neural-tube Defects. Maternal serum alpha-fetoprotein measurement in antenatal screening for onencephaly and spina bifida in early pregnancy. Lancet 1977;8026:1323-32.
14. Laurence KM. Fetal malformations and abnormalities. Lancet 1974;7886:939-41.
15. Roberts CJ, Hibbard BM, Elder GH, et al. The efficacy of a serum screening service for neural-tube defects: the South Wales experience. Lancet 1983;8337:1315-18.
16. Goodhart CB. Towards the prevention of spina bifida. Lancet 1974;7866:1110.
17. Brock DJH. Screening for neural tube defects. In: Srimgeour JB, ed. Towards the prevention of fetal malformation. Edinburgh: Edinburgh University Press, 1978:37-46.
18. Ellison-Nash DF. Neural-tube defects. Lancet 1978; 8062:438.
19. Brereton RJ, Cudmore RE, Irving IM, et al. Screening for neural-tube defects. Lancet 1978;8069:879.
20. Walker J. Ethical problems of screening for neural-tube defects. Lancet 1978;8085:373.
21. Department of Health and Social Security. Screening for spina bifida and other neural tube defects. Royal College of Obstetricians and Gynaecologists Archive, Working Group on Screening for Neural Tube Defects, 1973-1979, College Presidents' Records, 1977-1981, M10/1-3, unpublished circular.
22. Cooler, Roger. The resistible rise of medical ethics. Soc Hist Med 1995;4:257-70.
23. Lorber J. Early results of selective treatment of spina bifida. Lancet 1973;5886:201-4.
24. Zachary RB. Ethical and social aspects of treatment of spina bifida. Lancet 1968;7565:457.
25. Harris J. Ethical problems in the management of some severely handicapped children. J Med Ethics 1981;7:117-20.
26. Lorber J. Commentary one and reply to John Harris. J Med Ethics 1981;7:120-2.
27. Anscombe GEM. Commentary two. J Med Ethics 1981; 7:122-3.
28. Cusine DJ. Commentary three. J Med Ethics 1981; 7:123-4.
29. Davis A. Prenatal diagnosis. Lancet 1989;8671:1104.
30. Brock DJH, Wald N, Cuckle H. Organisation of maternal serum alphafetoprotein screening for fetal neural tube defects. Lancet 1977;8013:700-1.
31. Castel R. From dangerousness to risk. In: Burchill G, Gordon C, Miller P, eds. The Foucault effect: studies in governmentality. London: Harvester Wheatsheaf, 1991:281-98.
32. Althouse R. Neural-tube defects. Lancet 1978; 8062:439.
33. Chamberlain J. Human benefits and costs of a national screening programme for neural-tube defects. Lancet 1978;8103:1293-7.
34. MacIntyre A. After virtue: a study in moral virtue, 2nd edn. Duckworth: King's Lynn, 2004.
35. Oliver M. Understanding disability: from theory to practice. New York: Palgrave, 1996.
36. Comaish JS. How to set priorities in medicine. Lancet 1976;7984:512-4.
37. Meade TW. Our lives and hard times. Lancet 1975; 7944:1053-7.
38. Carter F, Hagard S. Screening for neural-tube defects. Lancet 1975;7946:1210.
39. Glass NJ, Cove AR. Cost-effectiveness of screening for neural tube defects. In: Srimgeour JB, ed. Towards the prevention of fetal malformation. Edinburgh: Edinburgh University Press, 1978:117-23.
40. Editorial. Screening for neural-tube defects. Lancet 1977; 8026:1345-7.
41. Polani P. Future developments in antenatal screening and diagnosis. In: Srimgeour JB, ed. Towards the prevention of fetal malformation. Edinburgh: Edinburgh University Press, 1978:261-71.
42. Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement: a screening test for Downs syndrome. Lancet 1984;8383:926-9.